Left Atrial Appendage Closure Devices Market to Reach USD 6.20 Billion by 2032

Left Atrial Appendage Closure Devices Market to Reach USD 6.20 Billion by 2032 as Low Treatment Penetration, Rising AF Ablation Volumes and Broader Stroke-Prevention Use Expand Procedure Demand

The Global Left Atrial Appendage Closure Devices Market was valued at approximately USD 2.20 billion in 2025 and is projected to reach approximately USD 6.20 billion by 2032, expanding at a CAGR of around 16.0% during 2026–2032. Market growth is increasingly supported by rising procedure volumes, low penetration across the eligible atrial fibrillation population, wider use of concomitant AF ablation and LAA closure, and expanding clinical evidence supporting device-based stroke prevention.

Approximately 150,000–160,000 percutaneous LAA closure procedures were performed globally in 2025, while more than 600,000 patients had received a WATCHMAN device cumulatively by 2025. Boston Scientific generated USD 1.958 billion in WATCHMAN revenue during 2025, accounting for nearly nine-tenths of the estimated global market. These figures show that LAA closure has developed into a major cardiovascular device category, but annual treatment volume remains low relative to the size of the potential patient population.

The United States remains the most important treatment market. At least 10.55 million U.S. adults are estimated to have diagnosed atrial fibrillation, equivalent to approximately 4.48% of the adult population. LAA closure candidates are concentrated among older and clinically complex patients. Historical registry data show a mean patient age of around 76 years, a mean CHA₂DS₂-VASc score of 4.8 and a mean HAS-BLED score of approximately 3.0. Around 70.1% of implanted patients had previous bleeding, 41.9% had gastrointestinal bleeding, 40.2% had previous stroke or TIA, 64.3% had a history of major bleeding and 35.5% had high fall risk.

Procedure volumes have expanded rapidly. Medicare LAAO procedures increased from 6,069 in 2017 to 29,083 in 2021, while the number of clinicians performing these procedures increased from 293 to 1,038. According to the findings, approximately 115,000–125,000 procedures were performed in the United States in 2025, compared with an addressable population estimated at approximately 2.0–2.5 million patients. This leaves annual treatment penetration at only around 5–6%, creating substantial room for further procedure growth.

Clinical evidence is also strengthening the market. An analysis of approximately 87,480 WATCHMAN procedures reported procedural success of around 94.2%, while earlier NCDR data showed that approximately 98.1% of deployed devices achieved less than 5 mm residual leak. More recent WATCHMAN FLX Pro surveillance included 21,589 attempted implantations between October 2023 and June 2024, demonstrating the increasing real-world scale of newer-generation devices.

The AF ablation pathway is becoming an increasingly important source of new LAA closure procedures. The OPTION trial enrolled approximately 1,600 patients and reported non-procedure-related major or clinically relevant nonmajor bleeding at 36 months in 8.5% of patients receiving LAA closure compared with 18.1% receiving oral anticoagulation. Following these results, the FDA expanded WATCHMAN FLX and FLX Pro indications in July 2025 for appropriate patients following AF catheter ablation. By September 2025, approximately 25% of U.S. WATCHMAN procedures were already being performed concomitantly with ablation.

Competition is led by Boston Scientific's WATCHMAN platform and Abbott's Amplatzer Amulet. The Amulet IDE trial enrolled 1,878 patients, with complete LAA occlusion achieved in 98.9% of Amulet patients versus 96.8% with Watchman 2.5. At five years, ischemic stroke or systemic embolism occurred in 7.4% of Amulet patients and 7.1% of Watchman patients, while major bleeding rates were almost identical at 20.1% and 20.0%.

Reimbursement is also supporting adoption. FY2025 national average Medicare inpatient payments were approximately USD 27,828 under MS-DRG 273, USD 22,211 under MS-DRG 274 and USD 44,026 under MS-DRG 317 for concomitant LAA closure and cardiac ablation.

Future market expansion could accelerate further if LAA closure gains a broader role as an alternative to long-term anticoagulation. Boston Scientific reported in March 2026 that the CHAMPION-AF study met its primary and secondary safety and efficacy endpoints, supporting regulatory submissions for broader first-line use. The company estimates an existing global WATCHMAN-addressable population of approximately 5 million patients, with potential expansion toward 20 million globally under broader indications.

By device type, endocardial LAA closure devices accounted for approximately USD 2.02 billion in 2025, or roughly 92% of market revenue. By procedure type, standalone closure represented approximately USD 1.67 billion, while ablation-associated closure accounted for approximately USD 530 million. Hospitals and integrated cardiovascular centers represented approximately USD 1.85 billion, reflecting their dominant role in structural-heart and electrophysiology procedures.

The Left Atrial Appendage Closure Devices Market is therefore expected to remain one of the faster-growing cardiovascular implant categories through 2032, supported by low treatment penetration, expanding procedure volumes, stronger clinical evidence, favorable reimbursement and potential widening of the eligible patient population.